Join Today's Clinical Laband David Miklos, MD, PhD, to discuss recent advances in bispecific CAR-T therapy and biomarkers for characterizing CAR-T product quality
The engineered T cells can target and attack pathogenic T cells in a mouse model of Type 1 diabetes
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.